Tumor Markers for Appendiceal Cancers

Carcinoid Tumors of the Appendix

Chromogranin A is the most useful general marker for appendiceal carcinoid tumors, with elevated levels associated with recurrence and poorer survival outcomes, as recommended by the National Comprehensive Cancer Network 1, 3
Elevated Chromogranin A levels, twice the normal limit or higher, correlate with shorter survival times in patients with metastatic neuroendocrine tumors, with a hazard ratio of 2.8, according to the National Comprehensive Cancer Network 4
5-Hydroxyindoleacetic acid, a serotonin metabolite, is particularly useful for serotonin-producing appendiceal carcinoids, as stated by the National Comprehensive Cancer Network 1, 2
Chromogranin B may be elevated when Chromogranin A is in the reference range, making it a useful additional marker, as noted in Gut 3
Pancreastatin is specifically elevated in metastatic neuroendocrine tumors and not affected by conditions that commonly elevate Chromogranin A, as reported in Gut 3

Chromogranin A levels can be falsely elevated in several conditions, including renal or hepatic insufficiency, concurrent use of proton pump inhibitors, and atrophic gastritis, as warned by the National Comprehensive Cancer Network and Chest 1, 2, 3, 5
5-HIAA measurements require strict dietary restrictions for 48 hours before and during collection, avoiding certain foods, coffee, alcohol, and smoking, and considering medications that can increase 5-HIAA, as advised by the National Comprehensive Cancer Network 1, 2
Rising Chromogranin A levels in an asymptomatic patient with stable imaging does not necessarily indicate the need for new therapy, as stated by the National Comprehensive Cancer Network and Chest 1, 5

These tumors should be managed according to colon cancer protocols rather than typical carcinoid protocols, as recommended by the National Comprehensive Cancer Network 1, 2

For typical appendiceal carcinoids ≤2cm without aggressive features, follow-up examinations are recommended as clinically indicated, with some institutions suggesting examination at 1 year post-appendectomy and then with decreasing frequency, as suggested by the National Comprehensive Cancer Network 2
For larger tumors or those with aggressive features, monitoring with Chromogranin A and 5-HIAA, as well as CT or MRI imaging, is recommended, as advised by Chest 5
Somatostatin receptor scintigraphy is not routinely recommended for surveillance after definitive resection but may be useful to assess disease location and burden in cases of suspected recurrence, as stated by the National Comprehensive Cancer Network 1, 2